Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
|Videos|July 25, 2017
Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer
Author(s)Ezra Cohen, MD
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.
Advertisement
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer (NK)-directed therapy in head and neck cancer.
Cohen says that NK cell-directed therapies can manipulate NKs ex vivo and then reinfuse them, or even create NKs from regular stem cells from the blood or skin.
Advertisement
Related to this article
Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5